Clinical impact of very early recurrence of atrial fibrillation after radiofrequency catheter ablation

Ukita, Kohei; Egami, Yasuyuki; Kawamura, Akito; Nakamura, Hitoshi; Matsuhiro, Yutaka; Yasumoto, Koji; Tsuda, Masaki; Okamoto, Naotaka; Matsunaga‐Lee, Yasuharu; Yano, Masamichi; Nishino, Masami; Tanouchi, Jun

doi:10.1016/j.jjcc.2021.08.004

Cited by 8 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for RFCA, VERAF was closely related to inflammatory response. 9 When it comes to CBA, however, there were no significant differences in inflammatory markers or myocardial injury markers after CBA among the three groups in our study, which indicates that VERAF after CBA is not so relevant to inflammatory response or myocardial injury. Previously, we reported an autopsy case after CBA for PAF.…”

Section: Discussioncontrasting

confidence: 66%

“…7 Moreover, we have recently examined the clinical impact of VERAF after RFCA and concluded that VERAF may have better clinical outcomes including lower incidence of LRAF and PV reconnections among patients with ERAF. 9 When it comes to CBA, on the other hand, Mugnai et al…”

Section: Discussionmentioning

confidence: 99%

“…7,8 As for RFCA, we have recently reported that very early recurrence of AF (VERAF) may have better clinical outcomes including lower incidence of late recurrence of AF (LRAF) and pulmonary vein (PV) reconnections among patients with ERAF. 9 However, little has been reported on the clinical impact of VERAF after CBA. The aim of this study was to evaluate the significance of VERAF after CBA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of very early recurrence of atrial fibrillation after cryoballoon ablation

Ukita

Egami

Kawanami

et al. 2022

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

Background Although much has been discussed about the early recurrence of atrial fibrillation (ERAF) after cryoballoon ablation (CBA), the clinical impact of very early recurrence of atrial fibrillation (VERAF) after CBA remains unclear. This study aimed to investigate the impact of VERAF after CBA. Methods We enrolled 236 consecutive patients who underwent an initial CBA for paroxysmal atrial fibrillation between February 2017 and December 2020 in our hospital. These patients were categorized into three groups: VERAF group who experienced an initial recurrence of atrial tachyarrhythmia within 48 h after CBA, late‐ERAF (LERAF) group who experienced an initial recurrence of atrial tachyarrhythmia between 48 h and 3 months after CBA, and non‐ERAF (NERAF) group who did not experience a recurrence of atrial tachyarrhythmia within 3 months after CBA. We investigated the late recurrence of AF (LRAF, defined as recurrence of atrial tachyarrhythmia more than 3 months after CBA), and the incidence of non‐pulmonary vein (PV) triggers in the patients who experienced a repeat ablation procedure due to LRAF. Results VERAF group had a higher incidence of freedom from LRAF than LERAF group (p = 0.032) and a lower incidence of freedom from LRAF than NERAF group (p = 0.002). Moreover, VERAF group had the highest incidence of non‐PV triggers at repeat ablation procedure among the three groups (p = 0.003). Conclusions While ERAF was a predictor of LRAF, VERAF was less related to LRAF among the patients with ERAF after CBA. Furthermore, VERAF might be associated with non‐PV triggers.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of very early recurrence of atrial fibrillation after cryoballoon ablation

Ukita

Egami

Kawanami

et al. 2022

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

show abstract

“…A study has reported that patients with early recurrence have a higher risk of late recurrence than patients without early recurrence, and early recurrence is a reliable predictor of late recurrence 7 . In patients with early recurrent atrial fibrillation (ERAF) (defined as recurrence of atrial tachyarrhythmia within 3 months after RFCA), very early recurrent atrial fibrillation (VERAF) may have better clinical outcomes, including lower incidence of late recurrent atrial fibrillation (LRAF, defined as recurrence of atrial tachyarrhythmia between 3 and 12 months after RFCA), and pulmonary vein (PV) reconnection 8 . Early recurrence of atrial tachyarrhythmia (ERAT) after ablation of persistent AF is closely related to late arrhythmia recurrence 9 .…”

Section: Introductionmentioning

confidence: 99%

“…7 In patients with early recurrent atrial fibrillation (ERAF) (defined as recurrence of atrial tachyarrhythmia within 3 months after RFCA), very early recurrent atrial fibrillation (VERAF) may have better clinical outcomes, including lower incidence of late recurrent atrial fibrillation (LRAF, defined as recurrence of atrial tachyarrhythmia between 3 and 12 months after RFCA), and pulmonary vein (PV) reconnection. 8 Early recurrence of atrial tachyarrhythmia (ERAT) after ablation of persistent AF is closely related to late arrhythmia recurrence. 9 Therefore, it is imperative to find new biomarkers for AF diagnosis and postoperative recurrence prediction.…”

Section: Introductionmentioning

confidence: 99%

High expression of long noncoding RNA plasmacytoma variant translocation 1 is an independent risk factor for recurrence after radiofrequency ablation in atrial fibrillation patients

Wang

Liao

Jiang

et al. 2022

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Atrial fibrillation (AF) is a common arrhythmia. Radiofrequency ablation (RFA) is the major AF treatment. Long noncoding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) is related to AF diagnosis. This study explored the clinical roles of PVT1 in AF. Totally, 168 AF patients and 100 healthy controls were selected. Plasma lncRNA PVT1 in AF patients before/after RFA was detected and the diagnostic efficacy and postoperative recurrence prediction value in AF were analyzed. Effects of plasma PVT1 expression on AF recurrence and its correlation with transforming growth factor beta 1 (TGF‐β1) in the recurrence and non‐recurrence groups were analyzed by Pearson coefficient. The risk factors of AF recurrence were evaluated. Plasma PVT1 was highly expressed in AF patients and diminished after RFA. PVT1 level >1.255 assisted AF diagnosis. The plasma PVT1 level in the recurrence group was higher than that of the non‐recurrence group. PVT1 level >1.525 assisted the prediction for postoperative recurrence. AF postoperative recurrence incidence in high PVT1 expression group was clearly higher than that in low PVT1 expression group, and plasma PVT1 expression in patients of the recurrence and non‐recurrence groups was positively correlated with TGF‐β1 content. High PVT1 expression was an independent risk factor for postoperative recurrence. Briefly, high PVT1 level assisted AF diagnosis and recurrence evaluation after RFA and was an independent risk factor for AF postoperative recurrence.

show abstract

Left atrial appendage peak flow velocity predicts improvement in mitral regurgitation after atrial fibrillation ablation

Yano¹,

Egami²,

Kawanami³

et al. 2024

Journal of Cardiology

View full text Add to dashboard Cite

Clinical impact of very early recurrence of atrial fibrillation after radiofrequency catheter ablation

Cited by 8 publications

References 20 publications

Impact of very early recurrence of atrial fibrillation after cryoballoon ablation

Impact of very early recurrence of atrial fibrillation after cryoballoon ablation

High expression of long noncoding RNA plasmacytoma variant translocation 1 is an independent risk factor for recurrence after radiofrequency ablation in atrial fibrillation patients

Left atrial appendage peak flow velocity predicts improvement in mitral regurgitation after atrial fibrillation ablation

Contact Info

Product

Resources

About